XENIOS is dedicated to translating medical need into pioneering therapies and devices together with caregivers and patients.
novalung was formed back in 2003. In 2011, the Aachen-based medos AG was acquired by novalung with the aim of extending medos’ blood pump expertise and blood pump technology for use with lung therapies. Compared to other pumps, the pulsatile blood pump system offered by medos was ideal for this kind of use. This also enabled the company to expand its overall product spectrum to offer both lung and heart support. This makes sense anatomically, since coronary and pulmonary circulation are interrelated. Logically, therefore, products are based on a single technology and use the same platform. The first joint project that resulted is i-cor: syncronized cardiac assist for treatment of cardiogenic shock and circulatory support during cath lab interventions.
In 2013, an initial step was then taken towards a full merger of these two businesses with the formation of a parent holding company, XENIOS.
One platform enabling next-generation therapies for lung and heart failures.
No other company except XENIOS AG is offering minimally invasive disposable lung and heart therapies on one single platform.
Issues with conventional lung or heart support.
Not only has XENIOS united lung and heart therapies into a single platform, but also its groundbreaking devices offer significant clinical advantages. Conventional therapies require an immobile, passive patient. Conventional mechanical ventilation is a 60-year-old technology that induces lung injury, pneumonia, and atrophy of the breathing muscles. ‘Tap water’-like continuous flow pumps do not synchronize with the heart’s rhythm.
XENIOS provides fundamental advantages with its minimally invasive lung and heart therapies.
With XENIOS, patients can be awake and mobile. Self-determined patients facilitate improved outcomes. There is no ventilator-associated lung injury, pneumonia, or atrophy of breathing muscles. XENIOS maintains a physiologic natural pulse to protect the heart and improve perfusion.
novalung — lung failure therapies.
One indication is COPD (Chronic Obstructive Pulmonary Disease). 50% of COPD patients have concomitant heart disease and 4 million undergo mechanical ventilation. They must be sedated to endure an endotracheal tube. The XENIOS novalung therapies offer an alternative to injurious, immobilizing mechanical ventilation.
i-cor — heart failure therapies.
One indication is for Cardiogenic Shock, or Decompensated Heart Failure. Given that one in two COPD patients have associated heart disease, the XENIOS platform is designed for physicians to treat the same patient who has certain lung and heart issues with one platform of minimally invasive products that do not require mechanical ventilation, sedation, and immobility.
Bottom line: XENIOS is focused on expanding leading products in a highly profitable yet under-penetrated market.
The XENIOS strategy is to build a highly profitable business in the US and Europe with upside potential in Asia. The company is generating significant revenues with a scalable business, direct sales in place in three EU countries, and global KOLs in place as product champions. XENIOS has clinically proven applications of its therapies with predictable execution. Regulatory approvals are in place (CE-marked, some products FDA-cleared, plus several Asian markets).